Literature DB >> 10608013

IgG Antibodies Against Factor VIII in Normal Individuals.

.   

Abstract

Previously, we found noninhibitory antibody against factor VIII in a hemophilic subject. We screened sera from normal and hemophilic individuals for the presence of similar antibodies. Sera from 18 normal individuals and 17 hemophilia A subjects were tested for the presence of factor VIII antibodies. We also tested two commercial immunoglobulin preparations for the presence of similar antibodies. Serum from two normal individuals were found to have IgG1 and IgG2 antibodies against factor VIII. The two commercial immunoglobulin preparations also contained IgG1 and IgG2 antibodies against factor VIII. Conclusions: Sera of apparently normal individuals contain antibodies to factor VIII with no inhibitory qualities. Such antibodies against factor VIII appear to be a common occurrence.

Entities:  

Year:  1995        PMID: 10608013     DOI: 10.1007/bf01064378

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  9 in total

1.  Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.

Authors:  I M Nilsson; E Berntorp; O Zettervall; B Dahlbäck
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

Review 2.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'.

Authors:  S Avrameas
Journal:  Immunol Today       Date:  1991-05

3.  Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

Authors:  M Algiman; G Dietrich; U E Nydegger; D Boieldieu; Y Sultan; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

4.  A new approach to immunologic identification of factor VIII antibodies.

Authors:  M Shurafa; K Kithier
Journal:  Haemophilia       Date:  1995-07       Impact factor: 4.287

5.  Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells.

Authors:  T Hironaka; K Furukawa; P C Esmon; M A Fournel; S Sawada; M Kato; T Minaga; A Kobata
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

6.  A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.

Authors:  K Peerlinck; J Arnout; J G Gilles; J M Saint-Remy; J Vermylen
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

7.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

8.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Authors:  J M Lusher; S Arkin; C F Abildgaard; R S Schwartz
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245

9.  FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.

Authors:  C A Fulcher; S de Graaf Mahoney; T S Zimmerman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

  9 in total
  1 in total

1.  Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis.

Authors:  A Abdi; M R Bordbar; S Hassan; F R Rosendaal; J G van der Bom; J Voorberg; K Fijnvandraat; S C Gouw
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.